Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.46 |
| ▸ | HTR2A | P28223 | 5/20 | 0.46 |
| ▸ | PSMB1 | P20618 | 3/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20786917 | 0.85 | HTR2A (0.52) | HTR2CHTR2APSMB1PSMB5GRM2 | |
| SCHEMBL1500208 | 0.80 | PSMB1 (0.43) | HTR2CHTR2APSMB1PSMB5GRM2 | |
| SCHEMBL20786907 | 0.79 | HTR7 (0.42) | HTR2CHTR2APSMB1PSMB5GRM2 | |
| SCHEMBL582152 | 0.78 | HTR2A (0.46) | HTR2CHTR2APSMB1PSMB5GRM2 | |
| SCHEMBL20808710 | 0.77 | PSMB1 (0.41) | HTR2CHTR2APSMB1PSMB5GRM2 | |
| SCHEMBL20809182 | 0.77 | PSMB1 (0.41) | HTR2CHTR2APSMB1PSMB5GRM2 | |
| SCHEMBL6923560 | 0.77 | GRM2 (0.55) | HTR2CHTR2APSMB1PSMB5GRM2 | |
| SCHEMBL1500147 | 0.76 | ERN1 (0.35) | HTR2CHTR2APSMB1PSMB5DAO | |
| SCHEMBL20786918 | 0.76 | PSMB1 (0.38) | HTR2CHTR2APSMB1PSMB5GRM2 | |
| SCHEMBL20808937 | 0.76 | PSMB5 (0.38) | HTR2CHTR2APSMB1PSMB5GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160208-A1 | DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-30 | — | — | US | disclosed |
| US-7902369-B2 | Diaryl-substituted five-membered heterocycle derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20070173507-A1 | Dairyl-substituted five-membered heterocycle derivative | MSD K.K. (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1726585-A1 | DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160208-A1 | DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE | OPRK1, GRM1, GRIK1 | HTR2C 86/4885HTR2A 366/4885PSMB1 3279/4885 |
| US-20070173507-A1 | Dairyl-substituted five-membered heterocycle derivative | OPRK1, OPRL1, GRM1 | HTR2C 162/4885HTR2A 606/4885PSMB1 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.